lirafugratinib
AssetAlso RLY-4008
Selectively inhibits FGFR2 signaling to suppress tumor growth.
- Stage
- Approved
- Modality
- Small molecule
- Target
- FGFR2
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Bile duct cancer
Approved, koreabiomed.com, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors5
Every asset’s record: target, stage, trials and the evidence behind it.